ISSN: 1001-0602
EISSN: 1748-7838
2012 impact factor 10.526*
(Thomson Reuters, 2013)
Free Sample Issue
 

VOLUME 29 ISSUE 8(8,2019): 601-602

 

pH-sensitive anti-CTLA4 antibodies: yes to efficacy, no to toxicity

 

Amnon Altman 1 and Kok-Fai Kong 1

 

1Division of Cell Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA

Correspondence:Amnon Altman (amnon@lji.org)        

 

For a long time, anti-CTLA-4 antibodies were believed to mediate their beneficial cancer immunotherapeutic effect (CITE), whose effectiveness and safety are limited by associated immune-related adverse effects (irAE), via blocking the interaction between CTLA-4 and its ligands, a mechanism known as checkpoint blockade. Using novel engineered antibodies, Zhang et al. challenge this paradigm in the present study, demonstrating that the irAE of anti-CTLA-4 antibodies can be uncoupled from their CITE, raising hopes for the design of a new generation of safer and more effective anti-CTLA-4 antibodies.

 
 
Browse  199

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
 
Home | Resources | Jobs | Contact Us
Copyright © 2013-2015 Institute of Biochemistry and Cell Biology, SIBS, CAS
您是第 位访问者,欢迎!
 沪ICP备05033115号